Social media

Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant in...

Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant in...

Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. htt...

Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. htt...

Join us for a focused discussion on early phase clinical trial strategies in neurodegenerative disease therapeutics. This session hosted by ASCPT will explore key considerations and share examples from studies in neurode...

ICON is at the World Drug Safety Congress in Boston. Visit us at booth \#227 to learn how ICON is advancing innovation in drug safety and pharmacovigilance. Our experts will share insights on risk management, patient s...

Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: ...

Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: ...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Are your trials measuring what matters to patients…or just what’s easiest to capture? It’s no longer enough to only drive outcomes. Rather, we must drive outcomes that matter to patients. In this whitepaper, we outlin...

Tired of stitching together fragmented market data? Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, rea...